Arena Pharmaceuticals Inc. (Nasdaq: ARNA) reported positive results from a Phase 2 study of ralinepag to treat pulmonary arterial hypertension. The stock price leaped $7.61 to close at $26.00.
Positive study results for Arena Pharmaceuticals
July 11, 2017 at 16:50 PM EDT
